When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Share this @internewscast.com

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.

“The news wasn’t good,” the widowed grandmother of two from Scone in regional NSW told 9news.com.au.

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Wendy Clift was diagnosed with breast cancer in 2007. (Supplied)

Just days later, she had a mastectomy, followed by more treatment.

While it was successful in keeping her in remission for a few years, the cancer has now returned and it has spread.

However, Clift, now 72, was invited to be part of a new Australian drug trial.

It’s hoped it could help patients with a certain kind of breast cancer live longer.

The DIAmOND clinical trial indicated that introducing dual immunotherapy alongside existing treatments might be beneficial for some patients suffering from advanced HER2-positive breast cancer.

Clift said her cancer appears to be “pretty stable” after the trial earlier this year, which she did at Lake Macquarie Private Hospital.

Some of the cancerous lumps she had have even disappeared, though she doesn’t know if that’s due to the new drug combination.

Clift said she didn’t have side effects.

She said taking part in the trial was less about her and more to help future patients.

“I’m just prepared because whatever happens to me is neither here nor there, but hopefully in years to come it’ll help somebody else,” she said.

Immunotherapy is a treatment that uses a person’s immune system to treat certain cancers.

When Wendy Clift went for a routine breast scan in 2007, she got call from her doctors almost immediately.
Wendy Clift, pictured with son Joshua and grandchildren Florence and Arthur, says she just wants to help future cancer patients. (Supplied)

The other drug used alongside this in the trial was trastuzumab, commonly known as Herceptin.

The trial focused on determining whether the combination could extend the period during which cancer remained controlled in patients with advanced conditions that had developed resistance to trastuzumab.

Results differed depending on the kind of cancer each of the 68 trial patients had.

Some had a response rate of up to 63 per cent, while for other kinds it was 27 per cent.

Some patients saw their cancer controlled for more than two years.

The combination of drugs has been given previously to people with lung cancer.

Professor Sherene Loi developed and led the trial, which was conducted by the research organisation Breast Cancer Trials.

“The encouraging findings imply that pairing new immunotherapy treatments with trastuzumab could provide a new treatment avenue for those with treatment-resistant HER2-positive breast cancer,” Loi stated.

“These findings provide a compelling case for further exploration and how we can best integrate this treatment combination into clinical practice.”

What is HER2-positive breast cancer?

HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2).

However, it often responds well to specific treatments.

Around 15-20 per cent of all types of breast cancers are HER2-positive.

It is more common in younger, pre-menopausal women.

Share this @internewscast.com
You May Also Like
A Camp Mystic sign is seen near the entrance to the establishment along the banks of the Guadalupe River after a flash flood swept through the area in Hunt, Texas, Saturday, July 5, 2025. (AP Photo/Julio Cortez)

Flash Floods in Texas Claim 37 Lives, Including 14 Children

The storm killed at least 37 people across the state, including 14…

Devastating Texas Floods: Over 32 Lives Lost and Many Children Still Unaccounted For

US authorities say 32 people, including 14 children are confirmed dead after…
TEHRAN, IRAN - JULY 6: (----EDITORIAL USE ONLY - MANDATORY CREDIT - 'IRANIAN LEADER PRESS OFFICE / HANDOUT' - NO MARKETING NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS----) Iranian Supreme Leader Ayatollah Ali Khamenei makes his first public appearance since the war with Israel by attending an Ashura ceremony in Tehran, Iran, on July 6, 2025. Khamenei, who did not join the previous three nights of Muharram mourning events held at his residence on Palestine Street, participated

Iran’s Supreme Leader Emerges Publicly for the First Time Since Onset of Iran-Israel Conflict

Khamenei’s absence during the war suggested heavy security for the Iranian leader,…

How Some Millionaires in Australia Avoid Paying Taxes and Who Might Be Worse

Avoiding tax can almost seem like a national sport in Australia, but…

Why the Emergence of This New Fire Ant Nest is a Nationwide Concern

The NSW government has confirmed the detection of a fire ant nest…
Two teenagers charged after allegedly crashing stolen car into tow truck on the Gold Coast

Teens Arrested Following Alleged Mercedes Theft and Collision with Tow Truck

Two teenagers have been charged over an alleged hit and run involving…

Tour de France Stage 1 Recap: Philipsen Triumphs in Windy Start, Evenepoel Caught in Breakaway

There were mixed outcomes for the multitude of Belgian fans who crossed…

Understanding Our Reactions to Emotional Displays in the Workplace

This week, UK chancellor Rachel Reeves gained international attention — not because…

Howard Advises Liberals to Reconsider Gender Quotas

Liberal veteran John Howard has warned against recent efforts to implement quotas…

‘Appalling behavior’: Prime Minister denounces synagogue assault, as police disclose new event

Victoria Police has not declared an arson attack at a Melbourne synagogue…
Man hit by police car in Darlinghurst

Police Car Strikes Man During Response to Sydney Brawl

A 35-year-old man was struck when he ran onto William Street in…

Devastating Texas Floods Claim Over 43 Lives; Numerous Children Still Unaccounted For

Some 43 people, including 15 children, have been confirmed dead following flash…